Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Altered Warning Recommends Modest Dosing of Anemia Drugs
The U.S. Food and Drug Administration has altered the Boxed Warnings and other enclosed literature in the packaging of Erythropoiesis-Stimulating Agents (ESAs) to indicate that, for safety reasons, they should only be used when absolutely necessary. The agency has determined that when ESAs are used to treat anemia in patients with chronic kidney disease, those individuals are at increased risk of suffering adverse cardiovascular events, including stroke and thrombosis.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The Second Circuit affirmed the lower courts' judgment that a "transfer made … in connection with a securities contract … by a qualifying financial institution" was entitled "to the protection of ... §546 (e)'s safe harbor ...."